CAR-T Cell Therapy for Liver and Lung Cancer - A Pipeline Analysis Report

CAR T-cell therapy for liver and lung cancer – An overview

The report provides comprehensive insights about all the pipeline molecules that fall under the chimeric antigen receptor (CAR) T- cell therapy for lung cancer including small cell lung cancer, non-small cell lung cancer, and lung squamous cell carcinoma and liver cancer including metastatic liver tumors, hepatocellular carcinoma, and liver metastases. Our market research analysts have predicted that with the introduction of CAR T-cell therapy as one of the most promising investigational approach to treat liver and lung cancer, the global liver and lung cancer market will witness growth in the forthcoming years.

Get A Free Sample

According to this pipeline analysis report, CARsgen Therapeutics (Humanized CAR-GPC3 T) and PersonGen Biomedicine (Anti-MUC1 CAR T cells) are focusing on the development of pipeline molecules for both liver cancer and lung cancer. Our market research analysts have also identified that researchers are evaluating majority of pipeline molecules for the treatment of liver cancer.

CAR T-cell therapy market report: Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of CAR T- cell therapy molecules for the treatment of liver and lung cancer. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the CAR T- cell therapy molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Sorrento Therapeutics
• MabVax Therapeutics
• Eureka Therapeutics

Therapeutic assessment of the CAR T-cell therapy pipeline for liver and lung cancer by route of administration

• Intrahepatic and intravenous
• Intratumoral
• Intrahepatic
• Intravenous

The pipeline therapeutics assessment for liver and lung cancer is majorly evaluated by the intratumoral route of administration, in which the drug is directly injected into the tumor. It has been estimated that the intratumoral route of administration will continue to be the major type of RoA in CAR T- cell therapy for liver and lung cancer.

Therapeutic assessment of the CAR T- cell therapy pipeline for liver and lung cancer by target

• AFP
• MUC1
• GPC3
• CEA

The CAR T-cell therapies developed by various companies for liver and lung cancer are being evaluated for the MUC1 target.

Want a bigger picture? Try a FREE sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Key questions answered in the report include

• What are the CAR T- cell therapy molecules in the various development stages for liver and lung cancer?
• What are the companies that are currently involved in the development of CAR T- cell therapy molecules for liver and lung cancer?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.